跳至主要内容
临床试验/NCT01784900
NCT01784900终止2 期

Treatment of Gastric Peritoneal Carcinomatosis by Association of Complete Surgical Resection of the Lesions and Intraperitoneal Immunotherapy Using Catumaxomab. A Randomized Phase II Trial.

Gustave Roussy, Cancer Campus, Grand Paris1 个研究点 分布在 1 个国家目标入组 26 人开始时间: 2012年11月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
终止
入组人数
26
试验地点
1
主要终点
Progression Free Survival

研究概览

简要总结

Treatment by association of complete surgical excision of the lesions and intraperitoneal immunotherapy using Catumaxomab for patients with gastric peritoneal carcinomatosis

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • consent form signed
  • Age >= 18
  • Carcinomatosis pre operative known or discivered in intraoperative
  • Patients uin good general condition who may have extent surgery associated to specific inflammatory syndrom of immunotherapy
  • Patients in good general condition
  • Patient insured to social care
  • Inclusion Criteria (intraoperative):
  • Gastric adenocarcinoma with macroscopic peritoneal carcinomatosis (PC) confirmed by extemporaneous histological examination
  • CP extension minimal or moderate (peritoneal index ≤ 12).
  • Resection of the entire macroscopic lesions detectable (primary tumor, lymph nodes and CP). cleaning D2 lymph node (or D1.5).

排除标准

  • Presence of metastasis in reach
  • Previous treatment with a non-humanized monoclonal AC- (mice or rat)
  • Hypersensitivity to any type of antibody.
  • History of cancer within 5 years preceding the entry in the trial other than basal cell skin carcinoma or in situ of the cervix,
  • Patients already included in another clinical trial with experimental molecule
  • Pregnant, or likely to be or breastfeeding, (Women of childbearing potential should have a pregnancy test (blood) negative 15 days before the date of the surgery) Using of a suitable method of contraception for patients of childbearing age during treatment. adequate contraception Methods includeare: an intrauterine device, hormonal contraception, condom use combined with a spermicide
  • Persons deprived of liberty or Trust (including curatorship)
  • Unable to undergo medical test for geographical, social or psychological.
  • Exclusion Criteria (intraoperative):
  • Persistent peritoneal lesions visible to the end of the surgery
  • Resection of the tail of the pancreas or pancreatic break (because no drainage post-op); break pleural (for K cardia)
  • Presence of metastasis in reach during surgery (except for ovarian metastasis

研究组 & 干预措施

Schema B (140µg)

Experimental
  • D0 : 20 μg of catumaxomab
  • D2 : 40 μg
  • D4 : 80 μg

干预措施: Catumaxomab 140µg (Drug)

Schema A (100µg)

Experimental
  • D0 : 10 μg of catumaxomab
  • D2 : 30 μg
  • D4 : 60 μg

干预措施: Catumaxomab 100µg (Drug)

结局指标

主要结局

Progression Free Survival

时间窗: every 3 months for the first two years

次要结局

  • Progression Free Survival(every 3 months for the first two years then every 4 months on year 3 then every 6 months on year 4 and 5)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验